TABLE 1.

Comparison of Baseline Clinical Characteristics in Three RAR Groupings by Enrollment by Clinical Sites in Low Patient-Weighted Mean RAR (low RAR countries) with Clinical Sites in High Patient-Weighted Mean RAR (high RAR countries)

Baseline Clinical Characteristics	RAR Groups 1 – 12			RAR Groups 13 – 21			RAR Groups 22 – 32
	Patients from Low RAR Countries n = 684	Patients from High RAR Countries n = 432	P	Patients from Low RAR Countries n = 252	Patients from High RAR Countries n = 308	P	Patients from Low RAR Countries n = 128	Patients from High RAR Countries n = 332	P
	Mean (S.D.)	Mean (S.D.)		Mean (S.D.)	Mean (S.D.)		Mean (S.D.)	Mean (S.D.)
Age	55.3 (7.6)	57.2 (8.2)	<0.001	63.3 (7.3)	66.4 (7.8)	< 0.001	66.5 (7.4)	68.3 (8.9)	0.026
LVEF	28.5 (5.2)	26.8 (5.8)	<0.001	26.5 (5.8)	26.1 (6.1)	0.532	25.3 (5.9)	23.8 (6.3)	0.021
CAD Severity Index	54.1 (19.3)	51.2 (18.0)	0.012	71.1 (20.7)	66.0 (20.9)	0.004	78.1 (18.4)	74.4 (20.1)	0.067

	n (%)	n (%)		n (%)	n (%)		n (%)	n (%)
Chronic Renal Insufficiency	0 (0.0)	0 (0.0)	--	0 (0.0)	0 (0.0)	--	35 (27.3)	137 (41.3)	0.006
NYHA HFClass I	87 (12.7)	64 (14.8)	<0.001	15 (5.9)	32 (10.4)	0.002	6 (4.7)	13 (3.9)	0.039
II	401 (58.6)	208 (48.2)		128 (50.8)	135 (43.8)		50 (39.1)	93 (28.0)
III	193 (28.2)	150 (34.7)		105 (41.7)	124 (40.3)		64 (50.0)	181 (54.5)
IV	3 (0.4)	10 (2.3)		4 (1.6)	17 (5.5)		8 (6.2)	45 (13.6)
Mitral Regurgitation 0	222 (32.5)	219 (50.7)	<0.001	43 (17.1)	109 (35.4)	< 0.001	20 (15.6)	85 (25.6)	0.003
1	282 (41.2)	158 (36.6)		118 (46.8)	124 (40.3)		40 (31.2)	125 (37.7)
2	46 (6.7)	27 (6.2)		44 (17.5)	49 (15.9)		34 (26.6)	79 (23.8)
3	14 (2.1)	3 (0.7)		10 (4.0)	6 (2.0)		16 (12.5)	17 (5.1)
4	120 (17.5)	25 (5.8)		37 (14.7)	20 (6.5)		18 (14.1)	26 (7.8)
Diabetes	166 (24.3)	157 (36.3)	<0.001	93 (36.9)	141 (45.8)	0.034	65 (50.8)	177 (53.3)	0.626